Latest Logos Global Management LP Stock Portfolio
$2.48Billion– No. of Holdings #51
Logos Global Management LP Performance:
2024 Q2: -5.7%YTD: 3.25%2023: 21.15%
Performance for 2024 Q2 is -5.7%, and YTD is 3.25%, and 2023 is 21.15%.
About Logos Global Management LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Logos Global Management LP reported an equity portfolio of $2.5 Billions as of 30 Jun, 2024.
The top stock holdings of Logos Global Management LP are IDYA, , MRUS. The fund has invested 4.8% of it's portfolio in IDEAYA BIOSCIENCES INC and 4.7% of portfolio in ARGENX SE.
The fund managers got completely rid off IMMUNOCORE HLDGS PLC (IMCR), GERON CORP (GERN) and CELLDEX THERAPEUTICS INC NEW (CLDX) stocks. They significantly reduced their stock positions in DYNE THERAPEUTICS INC (DYN), ROCKET PHARMACEUTICALS INC (RCKT) and ADVERUM BIOTECHNOLOGIES INC (ADVM). Logos Global Management LP opened new stock positions in ARGENX SE, MERUS N V (MRUS) and REVOLUTION MEDICINES INC (RVMD). The fund showed a lot of confidence in some stocks as they added substantially to JANUX THERAPEUTICS INC (JANX), COMPASS PATHWAYS PLC (CMPS) and ELEVATION ONCOLOGY INC (ELEV).
The top stock holdings of Logos Global Management LP are IDYA, , MRUS. The fund has invested 4.8% of it's portfolio in IDEAYA BIOSCIENCES INC and 4.7% of portfolio in ARGENX SE.
The fund managers got completely rid off IMMUNOCORE HLDGS PLC (IMCR), GERON CORP (GERN) and CELLDEX THERAPEUTICS INC NEW (CLDX) stocks. They significantly reduced their stock positions in DYNE THERAPEUTICS INC (DYN), ROCKET PHARMACEUTICALS INC (RCKT) and ADVERUM BIOTECHNOLOGIES INC (ADVM). Logos Global Management LP opened new stock positions in ARGENX SE, MERUS N V (MRUS) and REVOLUTION MEDICINES INC (RVMD). The fund showed a lot of confidence in some stocks as they added substantially to JANUX THERAPEUTICS INC (JANX), COMPASS PATHWAYS PLC (CMPS) and ELEVATION ONCOLOGY INC (ELEV).
Logos Global Management LP Equity Portfolio Value
Last Reported on: 27 Aug, 2024
Logos Global Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Logos Global Management LP made a return of -5.7% in the last quarter. In trailing 12 months, it's portfolio return was 27.23%.
New Buys
| Ticker | $ Bought |
|---|---|
| argenx se | 116,111,000 |
| merus n v | 100,589,000 |
| revolution medicines inc | 93,144,000 |
| disc medicine inc | 83,379,500 |
| moonlake immunotherapeutics | 65,955,000 |
| nuvalent inc | 29,585,400 |
| xenon pharmaceuticals inc | 29,242,500 |
| ionis pharmaceuticals inc | 28,596,000 |
New stocks bought by Logos Global Management LP
Additions
| Ticker | % Inc. |
|---|---|
| janux therapeutics inc | 900 |
| compass pathways plc | 798 |
| elevation oncology inc | 670 |
| xencor inc | 361 |
| spyre therapeutics inc | 360 |
| vera therapeutics inc | 230 |
| structure therapeutics inc | 205 |
| engene holdings inc | 200 |
Additions to existing portfolio by Logos Global Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| dyne therapeutics inc | -69.36 |
| rocket pharmaceuticals inc | -46.15 |
| adverum biotechnologies inc | -44.44 |
| boundless bio inc | -41.1 |
| immunovant inc | -35.21 |
| sarepta therapeutics inc | -25.00 |
| enliven therapeutics inc | -24.41 |
| astria therapeutics inc | -19.68 |
Logos Global Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| geron corp | -29,700,000 |
| immatics n.v | -10,510,000 |
| immunocore hldgs plc | -58,500,000 |
| cullinan oncology inc | -11,928,000 |
| viridian therapeutics inc | -12,257,000 |
| celldex therapeutics inc new | -27,280,500 |
| kyverna therapeutics inc | -12,420,000 |
| immunic inc | -555,963 |
Logos Global Management LP got rid off the above stocks
Sector Distribution
Logos Global Management LP has about 73.1% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 73.1 |
| Others | 26.9 |
Market Cap. Distribution
Logos Global Management LP has about 2.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 39.3 |
| UNALLOCATED | 26.9 |
| SMALL-CAP | 23.8 |
| MICRO-CAP | 6 |
| LARGE-CAP | 2.7 |
| NANO-CAP | 1.3 |
Stocks belong to which Index?
About 49.4% of the stocks held by Logos Global Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 50.6 |
| RUSSELL 2000 | 49.4 |
Logos Global Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Logos Global Management LP
Logos Global Management LP has 51 stocks in it's portfolio. About 35.3% of the portfolio is in top 10 stocks. IDYA proved to be the most loss making stock for the portfolio. MRUS was the most profitable stock for Logos Global Management LP last quarter.
Last Reported on: 27 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADVM | adverum biotechnologies inc | 0.23 | 833,332 | 5,716,660 | reduced | -44.44 | ||
| AGLE | spyre therapeutics inc | 1.09 | 1,150,000 | 27,036,500 | added | 360 | ||
| AKRO | akero therapeutics inc | 1.52 | 1,600,000 | 37,536,000 | added | 100 | ||
| ALLK | allakos inc | 0.23 | 5,800,000 | 5,800,000 | added | 100 | ||
| ANNX | annexon inc | 1.31 | 6,600,000 | 32,340,000 | added | 116 | ||
| APLS | apellis pharmaceuticals inc | 1.24 | 800,000 | 30,688,000 | unchanged | 0.00 | ||
| APLT | applied therapeutics inc | 0.22 | 1,200,000 | 5,323,800 | reduced | -11.11 | ||
| ATXS | astria therapeutics inc | 0.37 | 1,000,000 | 9,100,000 | reduced | -19.68 | ||
| AVTX | avalo therapeutics inc | 0.27 | 539,079 | 6,722,320 | new | |||
| CGEM | cullinan oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CLDX | celldex therapeutics inc new | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CMPS | compass pathways plc | 0.57 | 2,318,060 | 14,001,100 | added | 798 | ||
| CYBN | cybin inc | 0.88 | 80,000,000 | 21,680,000 | added | 100 | ||
| CYTK | cytokinetics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DSGN | design therapeutics inc | 1.36 | 10,065,000 | 33,717,800 | added | 100 | ||
| DYN | dyne therapeutics inc | 0.76 | 530,000 | 18,703,700 | reduced | -69.36 | ||
| ELEV | elevation oncology inc | 0.84 | 7,700,000 | 20,790,000 | added | 670 | ||
| ERAS | erasca inc | 1.12 | 11,800,000 | 27,848,000 | new | |||
| GERN | geron corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IDYA | ideaya biosciences inc | 4.82 | 3,400,000 | 119,374,000 | added | 126 | ||